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ABSTRACT 
Background 
Perianal abscess (PA) is associated with inflammatory bowel disease (IBD). The incidence of IBD after 
a diagnosis of PA and potential predictors of a future diagnosis of IBD are unknown. 
Methods 
The Health Improvement Network (THIN) is a primary care database representative of the UK 
population. Incident cases of PA were identified between 1995 and 2017. Subjects with PA were 
matched to controls within the same general practice. Primary outcome was subsequent diagnosis 
of Crohn’s Disease (CD) or ulcerative colitis (UC). A Cox regression model was used to assess 
potential predictors of a new diagnoses of CD or UC following PA.  
Results 
The risk of CD was higher in the PA cohort compared to controls; adjusted HR 7.51(95%CI 4.86-
11.62), p<0.0001. The risk of UC was also higher in the PA cohort compared to controls; adjusted HR 
2.03 (1.38-2.99), p<0.0001. Anaemia in men (HR 2.82(1.34-5.92), p=0.002), and use of antidiarrheal 
medications (HR 2.70(1.71-4.25), p<0.0001) were associated with an increased risk of CD following 
PA. Anaemia in men (HR 2.58(1.09-6.07), p=0.03), diarrhoea (HR 2.18(1.23-3.85), p=0.007) and use 
of anti-diarrhoeal medication (HR 2.27(1.19-4.30), p=0.012) were associated with an increased risk 
of UC following PA. 
Conclusion 
Subjects with PA are at an increased risk of subsequent diagnosis of CD and UC. Clinicians should 
strongly consider investigation for IBD in young patients presenting with diarrhoea and anaemia (in 
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men) following PA. Future research should discern appropriate screening strategies for this high-risk 
cohort. 
Key Words: Perianal Abscess, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis 
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BACKGROUND AND AIMS 
Perianal abscesses are caused by an infection of obstructed anal crypt glands resulting in a collection 
of pus. A previous cohort study1 conducted in Sweden estimated the incidence of  perianal abscesses 
to be around 16.1 per 100,000 people per year. Perianal abscesses can be complicated by fistulation, 
and systemic infection2. The primary management of perianal abscesses is surgical drainage.  
 
Perianal abscess has been identified as a potential early indicator of Crohn’s Disease (CD)3. The 
National Health Service conducted over 12,300 operations on perianal abscesses in 2016-2017. 
Perianal abscess surgery in an incident CD population in the United Kingdom (UK) was reported in a 
third of patients prior to their diagnosis of CD4. Perianal abscesses can also be associated with 
ulcerative colitis (UC) 5. It has therefore been suggested that cases of perianal abscesses be carefully 
followed up to monitor for the development of inflammatory bowel disease (IBD). 
 
The incidence of IBD in the West is slowing but a rapid increase in the Far East has been noted6. The 
advent of thiopurine and biologic therapy7 and their potential to alter disease course through 
mucosal healing8 has marked a shift in the therapeutic goals of IBD management. Perianal 
involvement in IBD (CD specifically), has been identified as an independent predictor of rapid 
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progression to ileocolonic disease and stricturing and penetrating behaviour9. Early identification of 
these patients would enable consideration of more effective medical treatment strategies such as 
thiopurines and biologics at an earlier disease stage and thereby potentially reduce the need for 
intestinal resection10 in this high-risk cohort.  However, no study to-date has examined the incidence 
of IBD subsequent to a diagnosis of perianal abscess and risk characterization of predictors of a 
future diagnosis of IBD within this cohort has not been attempted.  
Therefore, this study aims to assess the future risk of an IBD diagnosis, as well as identifying 
potential predictors for an IBD diagnosis following a presentation of perianal abscess with the 
intention of reducing diagnostic delay in IBD. 
 
METHODS 
Data Source: The Health Improvement Network 
The Health Improvement Network (THIN) is a primary care database consisting of 
electronically recorded person-level medical records derived from a population of 3.6 
million patients actively contributing to the dataset (sourced from 750 general practices), 
and deemed to be representative of the UK population11,12. Details of routine care including 
clinical diagnoses are recorded through use of a hierarchical coding system known as READ codes. 
Practices were eligible for inclusion in the study from the latest of the two following dates: either 
one year after the date of installation of the electronic medical record (EMR) system or after the 
practice’s acceptable mortality recording date. This ensured that the practice was making full use of 
the EMR system. To ensure baseline co-morbidities data was recorded, individual subjects were 
eligible for inclusion from the date their practice became eligible for inclusion in the study or one 
year after registration with their practice if this date was later. 
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The risk of future development of inflammatory bowel disease following perianal abscess  
Incident cases of perianal abscess diagnosed from 01 January 1995 to 01 December 2017 in the THIN 
network were identified by READ codes. Index date was assigned six months after presentation with 
perianal abscess to ensure a diagnosis of CD or UC was not made preceding presentation.  Subjects 
with perianal abscess were matched to up to 2 controls of the same age (+/- 1 year), gender, 
smoking and Body Mass Index (BMI) within the same general practice. Controls were defined as 
subjects who had never had a recorded diagnosis of perianal abscess at time of the study. Controls 
were assigned the same index date as their corresponding exposed subject to avoid immortality 
time bias. The primary outcome was the diagnosis of IBD (either CD or UC). The corresponding READ 
codes (appendix B) were identified in matched groups from the index date until the first of the 
following outcomes occurred (exit date); subject died, subject left practice, last data collection from 
practice or the subject was diagnosed with CD or UC. Any subjects with the outcome of interest prior 
to the index date were excluded from the study. 
Statistical Analysis 
Categorical baseline characteristics of the perianal abscess cohort and corresponding control group 
was assessed with the chi squared (χ2) test and are expressed in proportions. Parametric continuous 
variables such as age and body mass index (BMI) were assessed using two-sample t-tests and are 
expressed as mean (standard deviation). Non-parametric continuous variables were assessed with 
Mann-Whitney U test (person-years). Cox regression was used to provide an adjusted hazard ratio to 
estimate the likelihood of a diagnosis of CD or UC following a diagnosis of perianal abscess. The 
following co-variates were adjusted for: age, sex, BMI, diabetes, smoking and Townsend deprivation 
index (measure of material deprivation within a population derived from variables including 
unemployment, car and home ownership as well as household overcrowding)13. Cumulative hazard 
curves were derived for both CD and UC.  
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A cox regression model was used to assess potential predictors of a diagnosis of CD or UC following a 
diagnosis of perianal abscess. These were selected a-priori for inclusion in the regression model. The 
following factors were considered according to their presence closest in proximity to the index date: 
anaemia in males and females, abdominal pain, diarrhoea, lower gastrointestinal bleeding, and use 
of anti-diarrhoeal medication. Gonen and Heller’s K concordance statistic was computed to assess 
the ability of the cox regression model in predicting a diagnosis of CD, or UC following a diagnosis of 
perianal abscess. The median and interquartile range (IQR) of time from the diagnosis of perianal 
abscess to diagnosis of CD, or UC respectively was also reported.  Hazard ratios were calculated with 
95% confidence intervals and a statistical significance threshold of p<0.05.  Statistical analysis was 
performed on Stata v14.0 software.  
 
The THIN data collection scheme received multi-centre research ethics committee (MREC) approval 
in 2003 with scientific committee approval of this particular study in April 2018 (18THIN018) from 
‘IQVIA’ (data provider). 
 
RESULTS 
Demographics and co-morbidity in the matched perianal abscess and control groups 
There were 17,854 perianal abscess cases matched to 27,111 controls within the THIN database. 
There was a mean of 5.6(SD 4.2) and 5.4(SD 4.1) person years follow-up for perianal abscess subjects 
and controls respectively. The perianal abscess cohort contained a lower proportion of males 
compared to the control population; 11,857(66.4%) vs 17,333(63.9%), p<0.0001. Perianal abscess 
cases were slightly younger than controls as they were matched to within 2 years (45.8 vs 46.9 years, 
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p<0.0001). Both cohorts displayed no significant difference in current smoking or former smoker 
rates. The perianal abscess cohort had a higher mean BMI (28.1(SD 6.2) vs 27.2(SD 4.9), p<0.0001), 
increased use of oral steroid medication (2608(14.6%) vs 3112(11.5%), p<0.0001), an increased 
prevalence of anaemia (1121(6.3%) vs 1384(5.1%), a higher prevalence of diabetes mellitus 
(1700(9.5%) vs 1619(6%), p<0.0001) and had a higher proportion of the most deprived category of 
subjects (2607(14.6%) vs 3690(13.6%), p<0.0001) compared to the control population. Seventy-two 
patients were documented to have recurrent episodes of perianal abscess between the index date 
and exit date, and no patients were identified to have developed peri-anal fistulae or extra-intestinal 
manifestations including; ankylosing spondylitis, erythema nodosum, pyoderma gangrenosum, 
episcleritis, scleritis, uveitis or aphthous ulcers prior to diagnosis of IBD. Prior to the diagnosis of PA, 
60 patients had seen their GP on more than one occasion for symptoms of diarrhoea and 36 patients 
received anti-diarrhoeal medication on more than one occasion.  All demographic and baseline 
characteristics data for both perianal abscess cases and controls are presented in Table 1. 
 
The risk of Crohn’s disease and ulcerative colitis in the matched perianal abscess and control 
groups 
Following adjustment for potential confounding factors, the risk of CD was higher in the perianal 
abscess cohort compared to the control population; adjusted HR 7.51(95%CI 4.86-11.62), 
p<0.0001(Table 2). Mean age at CD diagnosis within the perianal abscess cohort was 38.51(SD 15.92) 
years. The median time from perianal abscess diagnosis to CD was 1.72(IQR 0.93-3.70) years. 
Cumulative hazard curve for CD is presented in Figure 1A. 
 
The risk of a subsequent diagnosis of UC was higher in the perianal abscess cohort compared to 
control population; adjusted HR 2.03(95%CI 1.38-2.99), p<0.0001(Table 2). Mean age at UC diagnosis 
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within the perianal abscess cohort was 50.46(SD 14.89) years. Median time from perianal abscess 
diagnosis to ulcerative colitis was 4.04(IQR 1.80-6.51) years. Cumulative hazard curve for UC is 
presented in Figure 1B. 
Subjects with diagnoses of CD or UC was pooled and the risk of IBD was found to be higher in the 
perianal abscess cohort compared to the control population; adjusted HR 3.86(95%CI 2.92-5.10), 
p<0.0001.  
 
Predictive variables of future development of Crohn’s Disease in perianal abscess subjects 
Cox regression was used to assess features that might indicate a future diagnosis of CD. Anaemia in 
men (HR 2.82(95%CI 1.34-5.92), p=0.002), and use of antidiarrheal medications (HR 2.70(95%CI 1.71-
4.25), p<0.0001) within 180 days of a diagnosis of perianal abscess were found to be associated with 
an increased likelihood of a diagnosis of CD in the future (Table 3). 
Similarly, several factors were found to be negatively associated with a future diagnosis of 
CD. These were:  BMI>30(HR 0.43(95%CI 0.24-0.78), p=0.005), and increasing age (HR 
0.97(95%CI 0.96-0.98), p<0.0001). On further investigation, the following age categories in 
particular were negatively associated with a future diagnosis of CD; 40-60 years (HR 
0.32(95%CI 0.14-0.71), p=0.005) and 60-80 years (HR 0.39(95%CI 0.16-0.95), p=0.04). The 
predictive accuracy of this regression model was assessed and a Gonen and Heller’s K value 
of 0.71 was derived. For individuals who developed Crohn’s disease in the exposed group, 
43 (30.7%), 40 (28.6%), 19 (13.6%) patients experienced abdominal pain, diarrhoea or lower 
GI bleeding respectively at any point prior to diagnosis of perianal abscess at index date of 
study.  
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Predictive variables of future development of ulcerative colitis in perianal abscess subjects  
Cox regression was also used to screen for potential predictors of a future diagnosis of UC. 
Anaemia in men (HR 2.58(95%CI 1.09-6.07), p=0.03), diarrhoea (HR 2.18(95%CI 1.23-3.85), 
p=0.007) and use of anti-diarrhoeal medication (HR 2.27(95%CI 1.19-4.30), p=0.01) within 
180 days of index date, were found to indicate an increased risk of future diagnosis of UC. In 
the perianal abscess cohort, BMI>30 was associated with a reduced risk of future diagnosis 
of UC (HR 0.41(95%CI 0.19-0.87), p=0.02) (Table 3).  The predictive ability of this model was 
assessed and a Gonen and Heller’s K value of 0.70 was derived. For individuals who 
developed ulcerative colitis in the exposed group, 16 (24.2%), 25 (37.9%), 11 (16.7%) 
patients experienced abdominal pain, diarrhoea or lower GI bleeding respectively at any 
point prior to diagnosis of perianal abscess at index date of study.  
 
Sensitivity Analysis 
Sensitivity analysis was carried out to ensure coding within the general practice was accurate and 
that the exposure was coded prior to the outcome. A latency period of 180 days was reduced to 0 to 
assess the effect on the future risk of IBD within the perianal abscess population. The risk of CD and 
UC in this analysis was: HR 10.49(95%CI 6.71-16.4), p<0.0001 and HR 2.54(95%CI 1.69-3.82), 
p<0.0001 respectively. 
 
DISCUSSION  
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This study has identified that a diagnosis of perianal abscess confers an increased risk of a 
subsequent diagnosis of CD and UC. The current study also identified predictors of a subsequent 
diagnosis of IBD in the perianal abscess population. Anaemia in men and prescription of anti-
diarrhoeal medication around the time of diagnosis of perianal abscess were found to indicate an 
increased risk of a future diagnosis of both inflammatory bowel diseases within this cohort. The 
median time from a diagnosis of perianal abscess to CD and UC was found to be 1.7 years and 4 
years respectively.  
 
The marked disparity between the risk ratios for developing CD and UC supports the traditional 
association between perianal abscess and predominantly Crohn’s disease. This study suggests that 
older subjects with perianal abscess are less likely to have a future diagnosis of CD compared to their 
younger counterparts, particularly those within the 40-60 and 60-80 age groups. This is similar to 
previous findings suggesting that older subjects, particularly those greater than 40 years of age, are 
at lower risk of complex perianal disease than their younger counterparts. Hamadani et al14 
identified the age category of <40 as being at higher risk of chronic perianal fistula following the 
initial presentation of perianal abscess; HR 2.12(95%CI 1.22-3.68), p<0.01. As the outcomes of this 
cohort study were limited to chronic anal fistula and recurrent anal sepsis, it is unclear whether any 
of these recurrent cases were actually manifestations of inflammatory bowel diseases. The elevated 
risk of complex perianal disease noted in the younger age category has also has been replicated in 
Chhaya et al4.  In this cohort study, the Montreal A2(17 to 40-year-old) category conferred an 
increased risk of perianal abscess surgery within the CD cohort compared to the A3 category (>40 
years old); HR 1.62(95%CI 1.29-2.02, p<0.001). No statistically significant association between 
increasing age and a future diagnosis of UC was discerned in the current study. Gender, diabetes and 
smoking status were not shown to be a statistically significant predictor of either of the 
inflammatory bowel diseases. 
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The present study suggests that subjects in the perianal abscess cohort with BMI > 30 were less 
likely to be diagnosed with CD and UC in the future. It has been previously shown that by Chan et 
al15 that obesity as measured by BMI is not associated with the development of incident ulcerative 
colitis or Crohn’s disease. This is in contrast to a similar large population-based prospective cohort 
study carried out in the Danish National Birth Cohort which suggested that obesity(BMI>30kg/m2) 
was a risk factor for Crohn’s disease16. Both Dong et al17 and Staborth-Akil18 suggest that high BMI 
had an association with a favourable prognosis, whereas low BMI was associated with a more severe 
disease course. In the context of this study, subjects with undiagnosed IBD could potentially have 
had low BMI due to the pathological processes underlying IBD, leading to a perceived decrease in 
risk of a future diagnosis of IBD in subjects with high BMI.   
 
Anaemia was shown to be a strong predictor of both inflammatory bowel diseases in the current 
study but only among men. The presence of anaemia at the time of diagnosis of IBD is a well-
recognised feature19. The prevalence of anaemia in an IBD inception cohort has been reported be as 
high as 48.8% in CD patients and 20.2% in UC patients 20. A gender difference in the prevalence of 
anaemia in IBD was also described with a higher proportion of males being affected than females in 
both of the inflammatory bowel diseases. The present study confirms this distribution with men 
affected more than women in both CD and UC; 8.5% vs 7.7% and 12.5% vs. 0% respectively.  
 
Prescription of anti-diarrhoeal medication around the time of diagnosis of perianal abscess was 
associated with a subsequent diagnosis of inflammatory bowel disease. Reporting diarrhoea was 
also associated with a future diagnosis of UC alone. In the context of this study, this finding suggests 
that reporting diarrhoea is a key marker of undiagnosed IBD. Hence this symptom would merit 
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further investigation, e.g. faecal calprotectin testing. However, symptoms such as abdominal pain, 
lower gastrointestinal tract bleeding at the time of diagnosis of perianal abscess were not associated 
with a future diagnosis of either IBD.  
 
Diagnostic delay remains a significant global challenge in the management of IBD, particularly CD21. 
This is known to have a significant adverse effect on disease course22. Recent cohort studies suggest 
the median time from symptoms to diagnosis of CD has been shorter than 1 year23,24. In contrast, 
median time from a diagnosis of perianal abscess to CD and UC in the current study was found to be 
1.7 and 4 years respectively. This delay might potentially represent an opportunity for early 
detection and early therapeutic intervention of IBD in a potentially high-risk cohort.  
 
The findings of this study rely upon accurate coding of the diagnosis of perianal abscess and the 
other baseline variables. The perianal abscess cohort in the present study resembles previous 
descriptions of subjects with this disease in the literature. The male predominant gender ratio of 2:1 
(M: F) and relatively high proportion of smokers(40.87%) is similar to the gender ratio (2.4:1) in 
Adamo et al1 and proportion of smokers(48.6%) in Devaraj et al25 respectively. IBD has also been 
well-validated in the General Practice Research Database (GPRD) – a precursor to the THIN 
database26. The inability of this study to conclusively discern whether perianal abscess was in fact 
the initial manifestation of underlying undiagnosed inflammatory bowel disease itself, as opposed to 
a stand-alone condition is a significant limitation. However, this does not affect one of the key 
objectives of this study; enabling a reduction in diagnostic delay of IBD. This study adjusts for the 
varied role of smoking, however there may yet be unknown confounders that may affect the 
development of IBD. It is also clear from the baseline data that the exposed cohort had a higher 
prevalence of patients using oral steroids prior to index date. As we were unable to quantify the 
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indications for this prescription it is possible that patients in this cohort had comorbidities that 
necessitated steroid prescription. 
 
The findings of this study in addition to knowledge that diagnostic delay22 and perianal involvement 
in IBD can be a prognostic indicator of a severe disease course27 confers great onus on the physician 
for early identification of IBD. Physicians should have a low threshold for investigation to screen for 
IBD in the PA cohort, particularly in the younger cohort (<40 years of age), males with anaemia and 
patients using antidiarrhoeals around the time of the diagnosis of perianal abscess. 
 
This is the first study to report the incidence of IBD in patients who have had a prior diagnosis of 
perianal abscess. The results suggest that patients with a diagnosis of perianal abscess are at an 
increased risk of having a subsequent diagnosis of Crohn’s disease and ulcerative colitis. This study 
was also able to establish predictive features of inflammatory bowel disease to assist in the risk-
stratification of this patient population in the clinical setting.  
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FIGURE LEGENDS 
Fig 1A: Cumulative hazard curve for Crohn’s disease 
Fig 1B: Cumulative hazard curve for ulcerative colitis 
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TABLES 
Table 1: The Health Improvement Network perianal abscess and matched control group 
characteristics 
  Perianal 
Abscess Cases 
Control  
Number of outcomes 
 
17,854 27,111 
Person years of follow-up 
(SD) 
5.6 (4.2) 5.4 (4.1) 
Age (SD) 45.8 (15.6) 46.9 (15.2) 
Male Sex 11,857 (66.4%) 17,333 (63.9%) 
Body mass index (SD) 28.1 (6.2) 27.2 (4.9) 
Current smoker 7297 (40.9%) 11156 (41.2%) 
Ex-Smoker  3,451 (19.3%) 5,363 (19.8%) 
Anaemia  1121 (6.3%) 1384 (5.1%) 
Diabetes mellitus 
 
1700 (9.5%) 1619 (6%) 
Townsend index*                   1 3497 (19.6%) 5800 (21.4%) 
2 3230 (18.1%) 5084 (18.8%) 
3 3461 (19.4%) 5178 (19.1%) 
4 3312 (18.6%) 4733 (17.5%) 
5 2607 (14.6%) 3690 (13.6%) 
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Not available 1747 (9.8%) 2626 (9.7%) 
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     Standard Deviation (SD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: The incidence of Crohn’s Disease and Ulcerative colitis among the perianal abscess subjects 
and controls 
 
 Crohn’s Disease Ulcerative Colitis 
  Perianal Abscess Control 
Population 
Perianal Abscess  Control 
Population 
Number of 
Outcomes 
140 25 66 49 
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* Adjusted for age, sex, BMI, diabetes, smoking and Townsend deprivation score  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Person-years 99,802.8 147,088.1 100,156.5 147,034.2 
Incidence Rate  
(per 100,000 
person-years) 
0.0014 0.0008 0.0007 0.0003 
Incidence Rate 
Ratio  
(95% CI) 
8.25 (5.39-12.63) 2.02 (1.39-2.93) 
p-value <0.0001 <0.0001 
Adjusted* 
Hazard Ratio  
(95% CI)  
7.51 (4.86-11.62) 2.03 (1.38-2.99) 
p-value <0.0001 <0.0001 
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Table 3: The predictive variables for future development of Crohn’s Disease and ulcerative colitis 
within the perianal abscess cohort 
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                                                                          Crohn’s Disease Ulcerative Colitis 
  HR 95% CI p-value HR 95% CI p-value 
Gender Male 1 ref ref 1 ref ref 
Female 1.31 0.89-1.92 0.17 0.88  0.50-1.55 0.66 
Age  
(Continous) 
 0.97 0.96-0.98 <0.0001 1.00  0.98-1.01 0.64 
Age  
(Categorical) 
20 < x <= 40 years   0.78 0.37-1.64 0.52    
40 < x <= 60 years   0.32 0.14-0.71 0.005    
60 < x <= 80 years   0.39 0.16-0.95 0.04    
80 to max years 0.14 0.02-1.17 0.07    
BMI <25 1 ref ref 1 ref ref 
25-30 0.82 0.52-1.28 0.38 0.59 0.31-1.11 0.1 
>30 0.43 0.24-0.78 0.005 0.41  0.19-0.87 0.02 
Diabetes  0.42 0.15-1.16 0.1 0.85  0.33-2.22 0.74 
Smoking Never Smoker 1 ref ref 1 ref ref 
Current Smoker  0.90 0.60-1.34 0.59 1.18 0.66-2.11 0.57 
Ex-Smoker  1.15 0.70-1.89 0.58 1.15 0.57-2.32 0.71 
Abdominal Pain  1.33 0.91-1.93 0.14 0.71 0.39-1.29 0.26 
Anaemia Men 2.82 1.34-5.92 0.002 2.58 1.09-6.07 0.03 
Women 1.24 0.52-2.93 0.63 *calculation not feasible due to low number of 
outcomes 
Diarrhoea  1.33 0.87-2.02 0.18 2.18 1.23-3.85 0.007 
Lower GI Bleed  1.60 1.00-2.56 0.05 1.83 0.98-3.43 0.06 
Use of Anti-
Diarrhoeals 
 2. 70 1.71-4.25 <0.0001 2.27 1.19-4.30 0.01 
Townsend 1 1 ref ref 1 ref ref 
2 0.56 0.31-1.01 0.05 1.45 0.71-3.00 0.31 
3 0.91 0.55-1.51 0.71 1.24 0.59-2.61 0.58 
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Hazard Ratio (HR); Body Mass Index (BMI); 95% Confidence Interval (95% CI) 
 
 
 
 
 
FIGURES 
 
Fig 1A: Cumulative hazard curve for Crohn’s disease 
 
 
 
4 0.71 0.41-1.23 0.22 0.97 0.43-2.18 0.94 
5 1.00 0.59-1.69 0.993 0.72 0.28-1.81 0.48 
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Fig 1B: Cumulative hazard curve for ulcerative colitis 
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